Comparing two treatments for advanced breast cancer with low hormone receptor
Part of Cancer clinical trials.
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have advanced breast cancer confirmed by biopsy.
- Your cancer is hormone receptor low (1-50% ER positive by IHC, or ER under 1% with PR 1% or more, or other patterns your doctor can evaluate).
- Your cancer is HER2-negative (IHC 0 or 1+, or FISH negative if IHC 2+).
- You have at least one measurable tumor lesion.
- You have not had chemotherapy for advanced disease, but you may have had hormone therapy.
- You have not taken a CDK4/6 inhibitor before, or if you did, your cancer came back more than 1 year after stopping.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This trial compares two treatment approaches in people with high-risk hormone-positive, HER2-negative breast cancer that has spread to certain lymph nodes. It looks at which option works best to lower cancer returning and to control the disease after surgery and initial chemotherapy.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.